Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 6.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTIONIS PHARMACEUTICALS INC's latest supported as-filed period reports revenue of $267.9M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 6.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 211.06% · OPTIONAL
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 18.97% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 98.98% · CORE
Level · gp.fundamentals.operating_margin
Raw value -38.18% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 17.02% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 499.4%; Inventory / revenue moved 1710 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 17.7%; Operating cash flow increased 273.7%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 30.7%; Capex / revenue moved 328 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 4.3%; SBC / revenue moved 1045 bp higher.
2 evidence-backed componentsInventory changed +499.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
IONS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001140361-26-035802SEC ↗8-KSep 4, 2026Period Sep 3, 20260001140361-26-035657SEC ↗4Sep 2, 2026Period Aug 31, 20260000874015-26-000262SEC ↗4Sep 2, 2026Period Aug 31, 20260000874015-26-000261SEC ↗4Sep 2, 2026Period Aug 31, 20260000874015-26-000260SEC ↗4Sep 2, 2026Period Aug 31, 20260000874015-26-000259SEC ↗4Jul 31, 2026Period Jul 30, 20260000874015-26-000254SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 31, 2026Filed Sep 2, 2026 | BENNETT C FRANKEVP, Chief Scientific Officer | OtherDirect | 110 | $51 | $5,644 | Form 4 ↗ |
| Jul 31, 2026Filed Jul 31, 2026 | Hayden Michael RDirector | Open Market PurchaseIndirect | 5,000 | $52 | $258,000 | Form 4 ↗ |
| Jul 30, 2026Filed Jul 31, 2026 | Hayden Michael RDirector | Open Market PurchaseIndirect | 15,000 | $53 | $800,700 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Working capital changed +29.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed +174.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Working capital / assets changed +1638 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Free-cash-flow proxy changed +295.2% from the comparable as-filed period.
Operating cash flow changed +273.7% from the comparable as-filed period.
Operating margin changed -6911 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0000874015-26-000251